Want to see FR:ALIKO full AI Analyst Report?
Ikonisys SA (ALIKO) AI Stock Analysis
Ikonisys SA
(Paris:ALIKO)
The score is primarily constrained by weak financial performance—persistent, sizable losses and ongoing cash burn—despite strong recent revenue growth and a comparatively healthier balance sheet. Technicals add further pressure as the stock trades below major moving averages with negative MACD, while valuation is also penalized because profitability is negative and there is no dividend support.
Ikonisys SA (ALIKO) vs. iShares MSCI France ETF (EWQ)
- Market Cap
- EUR 22.42M
- Dividend Yield
- ―
- Average Volume (3M)
- 2,847
- Price to Earnings (P/E)
- -5.2
- Beta (1Y)
- 0.24
- Revenue Growth
- 37.28%
- EPS Growth
- 7.83%
- Country
- France
- Employees
- 15
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Ikonisys SA Business Overview & Revenue Model
Company Description
Based in Paris, France, Ikonisys S.A. is a company specializing in cell-based diagnostics. It develops, produces, and commercializes medical diagnostic solutions for various cancers across the United States and Europe. Their core offering includes th...
How the Company Makes Money
Ikonisys SA primarily makes money by selling (1) its diagnostic/cytogenetics instrumentation platforms (automated imaging and analysis systems) and (2) recurring consumables and related products used with those platforms (e.g., assay/reagent kits and...
Ikonisys SA Financial Statement Overview
Summary
Strong revenue acceleration and solid gross margin are outweighed by very large, widening operating losses and persistent negative free cash flow. The balance sheet is relatively supportive with modest and improving leverage, but negative returns and ongoing cash burn keep overall financial quality below average.
Income Statement
24NegativeBalance Sheet
63PositiveCash Flow
28Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.01M | 1.39M | 1.01M | 448.56K | 935.22K | 365.14K |
| Gross Profit | 715.37K | 897.27K | 715.37K | 255.83K | 751.80K | 28.46K |
| EBITDA | -1.70M | -1.28M | -1.77M | -927.41K | -1.35M | -483.65K |
| Net Income | -3.24M | -4.20M | -3.24M | -2.27M | -2.45M | -571.27K |
Balance Sheet | ||||||
| Total Assets | 27.40M | 26.71M | 27.40M | 20.85M | 21.72M | 22.52M |
| Cash, Cash Equivalents and Short-Term Investments | 25.08K | 1.03M | 25.08K | 9,402 | 93.98K | 1.52M |
| Total Debt | 4.13M | 3.25M | 4.13M | 3.40M | 2.51M | 1.24M |
| Total Liabilities | 13.14M | 7.58M | 13.14M | 5.12M | 4.04M | 2.50M |
| Stockholders Equity | 14.25M | 19.13M | 14.25M | 15.73M | 17.67M | 20.01M |
Cash Flow | ||||||
| Free Cash Flow | 0 | -1.17M | -1.37M | -1.46M | -2.01M | -1.36M |
| Operating Cash Flow | 0 | -1.16M | -1.33M | -914.22K | -1.14M | -781.42K |
| Investing Cash Flow | 0 | -301.62K | -67.58K | -545.24K | -884.20K | -636.56K |
| Financing Cash Flow | 0 | 2.36M | 1.41M | 1.37M | 599.13K | 2.90M |
Ikonisys SA Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALIKO, the sentiment is Neutral. The current price of 1.42 is above the 20-day moving average (MA) of 1.41, below the 50-day MA of 1.42, and below the 200-day MA of 1.49, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 51.66 is Neutral, neither overbought nor oversold. The STOCH value of 76.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FR:ALIKO.
Ikonisys SA Peers Comparison
Overall Rating
FR:ALERS58Neutral- FR:ALIKO46Neutral
FR:ALNOV45Neutral
FR:ALMDT43Neutral
FR:ALMKT41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| FR:ALERS | 58Neutral | EUR 258.39M | 37.57 | 3.89% | ― | 6.28% | 204.56% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| FR:ALIKO | 46Neutral | EUR 22.42M | -5.20 | -22.03% | ― | 37.28% | 7.83% |
| FR:ALNOV | 45Neutral | EUR 31.94M | -0.77 | -159.70% | ― | 10.36% | 29.41% |
| FR:ALMDT | 43Neutral | EUR 180.85M | -3.00 | 271.64% | ― | 2.16% | -5.26% |
| FR:ALMKT | 41Neutral | EUR 18.94M | 1.53 | -157.72% | ― | 3.38% | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FR:ALIKO | Ikonisys SA | 1.42 | -0.04 | -2.74% | |
| FR:ALMKT | MAUNA KEA TECHNOLOGIES | 0.10 | -0.00 | -1.02% | |
| FR:ALNOV | Novacyt S.A. | 0.44 | -0.02 | -4.35% | |
| FR:ALERS | Eurobio-Scientific SA | 26.30 | 2.15 | 8.90% | |
| FR:ALDMS | Diagnostic Medical Systems | 0.91 | -0.41 | -30.95% | |
| FR:ALMDT | Median Technologies | 3.69 | 0.79 | 27.24% |
Ikonisys SA Corporate Events
Aliko Scientific signs Romanian and Saudi distribution deals to boost cancer diagnostics reach
Aliko Scientific has expanded its international footprint in cancer diagnostics by signing distribution agreements in Romania with Proton Impex 2000 and in Saudi Arabia with H-Care Medical Est., covering its portfolio in liquid-based cytology, FISH,...
Aliko Scientific boosts revenue and advances integrated oncology platform despite wider net loss
Aliko Scientific reported a 52.6% rise in total revenue to €1.64 million for 2025, driven by the full-year consolidation of Hospitex and the rollout of its integrated oncology diagnostics offering. EBITDA loss narrowed by about a third to ̈́...
Aliko Scientific Subsidiary Hospitex to Study National Urine24 Cancer Screening in Uzbekistan
Aliko Scientific’s subsidiary Hospitex International has signed an agreement with the Jizzakh branch of Uzbekistan’s Republican Scientific and Practical Centre for oncology and radiology to develop a feasibility study for a national urina...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 17, 2026